arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cytek Biosciences, Inc.

CTKB
$5.38 ▼ -0.50 (-8.50%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
27 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cytek Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $696.5M
Dividend Yield —
Revenue Growth 5.6% ↘
Op. Margin -23.7% ↗
ROIC -2.8% ↗
FCF / Share $-0.01 ↗
Trailing P/E —
Price / Book 2.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$48.14M
↑ +5.6% —
Net Income Profit after all expenses
$-18.87M
↓ -65.5% —
Operating Margin Operating profit as % of sales
-23.7%
↑ +43.4% 10th
FCF / Share Free cash flow per share
$-0.01
↑ +82.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
11
Returns
28
Cash Quality ↑
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters